Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

Presentation THT 2025

HFpEF in Focus: The Scientific Rationale for the Confirmatory RESPONDER HF Trial

Presenter: Sanjiv Shah

February 12, 2025

Presentation THT 2025

What Endpoints are Relevant for Evaluating how Interatrial Shunts Provide Clinical Benefit: Hemodynamic Exercise Testing and Beyond

Presenter: Sanjiv Shah

February 11, 2025

Presentation THT 2025

Atrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial

Presenter: Sanjiv Shah

February 11, 2025

Presentation THT 2025

How Regulation of Stressed Blood Volume at Rest and Exercise Contributes to HFpEF Symptomatology

Presenter: Sanjiv Shah

February 11, 2025

Presentation THT 2024

PH-HFpEF: Levosimendan

Presenter: Sanjiv J. Shah

March 06, 2024

Presentation THT 2024

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: REBALANCE-HF Randomized Trial 12-Month Results

Presenter: Sanjiv J. Shah

March 05, 2024

Presentation THT 2024

Patient Selection Considerations for Trials of Interatrial Shunts

Presenter: Sanjiv J. Shah

March 05, 2024

Presentation THT 2024

HFpEF Diagnosis and Treatment: : Where Do We Stand in 2024?

Presenter: Sanjiv J. Shah

March 04, 2024

Presentation THT 2024

Right Heart Function and Flow Dynamics with Different Left-to-Right Shunt Approaches

Presenter: Sanjiv J. Shah

March 04, 2024

News Conference News THT 2023

More Early Insights Into Interatrial Shunts in HF, but Little to Focus the Field

Shelley Wood

March 24, 2023

Presentation THT 2023

Update on the Phase 2 REBALANCE-HF Trial of SAVM for HFpEF/HFmrEF: Lessons Learned and Future Directions

Presenter: Sanjiv Shah

March 21, 2023

Presentation THT 2023

IASDs: What We Know and What We Don't Know

Presenter: Sanjiv Shah

March 20, 2023

Presentation THT 2023

Interventional Therapies for HFpEF

Presenter: Sanjiv Shah

March 20, 2023

Presentation THT 2022

AXON Therapeutics

Presenter: Sanjiv J. Shah

February 02, 2022

News Conference News THT 2022

REDUCE LAP-HF II: Atrial Shunt Device Comes Up Short in HFpEF

Shelley Wood

February 01, 2022

Presentation THT 2022

Physiological Phenotyping

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

Long-term follow-up on FIH experience using the Satera Ablation System in HFpEF and HFrEF

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

REDUCE LAP-HF II Randomized Study of the Corvia Atrial Shunt -- Primary Results

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

CON - PRO - LA decompression is unnecessary in the era of SGLT2 inhibitors and ARNI's!

Presenter: Sanjiv Shah

February 01, 2022

Advertisement

HFpEF in Focus: The Scientific Rationale for the Confirmatory RESPONDER HF Trial

What Endpoints are Relevant for Evaluating how Interatrial Shunts Provide Clinical Benefit: Hemodynamic Exercise Testing and Beyond

Atrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial

How Regulation of Stressed Blood Volume at Rest and Exercise Contributes to HFpEF Symptomatology

PH-HFpEF: Levosimendan

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: REBALANCE-HF Randomized Trial 12-Month Results

Patient Selection Considerations for Trials of Interatrial Shunts

HFpEF Diagnosis and Treatment: : Where Do We Stand in 2024?

Right Heart Function and Flow Dynamics with Different Left-to-Right Shunt Approaches

More Early Insights Into Interatrial Shunts in HF, but Little to Focus the Field

Update on the Phase 2 REBALANCE-HF Trial of SAVM for HFpEF/HFmrEF: Lessons Learned and Future Directions

IASDs: What We Know and What We Don't Know

Interventional Therapies for HFpEF

AXON Therapeutics

REDUCE LAP-HF II: Atrial Shunt Device Comes Up Short in HFpEF

Physiological Phenotyping

Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF

Long-term follow-up on FIH experience using the Satera Ablation System in HFpEF and HFrEF

REDUCE LAP-HF II Randomized Study of the Corvia Atrial Shunt -- Primary Results

CON - PRO - LA decompression is unnecessary in the era of SGLT2 inhibitors and ARNI's!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content